KLTO Stock Summary and Trading Ideas (Klotho Neurosciences | NASDAQ:KLTO)

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Klotho Neurosciences trades on the NASDAQ stock market under the symbol KLTO.

As of January 23, 2026, KLTO stock price declined to $0.33 with 457,143 million shares trading.

KLTO has a beta of 1.59, meaning it tends to be more sensitive to market movements. KLTO has a correlation of 0.01 to the broad based SPY ETF.

KLTO has a market cap of $23.67 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that KLTO belongs to (by Net Assets): VXF.

KLTO has underperformed the market in the last year with a price return of -25.8% while the SPY ETF gained +14.2%. KLTO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.4% and -3.5%, respectively, while the SPY returned +2.9% and -0.7%, respectively.

KLTO support price is $.32 and resistance is $.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KLTO shares will trade within this expected range on the day.